Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.Key Timestamps01:04 - Guest Introduction03:45 - FDA Indication for Obesity08:45 - SURMOUNT-217:40 - SURMOUNT-3 and -422:00 - Future of Incretin Therapies

Episode metadata supplied by the publisher feed · Published Mar 18, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD

0:00 24:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 24 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on March 18, 2024.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!